Data, patients and payers key to “New Health” success, says Quintiles |
![]() |
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support. Related news |
Covance has recorded a 29 per cent drop in operating income, despite revenue growth, as cost reduction actions and Phase III delays hit margins.
CRO Chiltern International says market share grew in fiscal 2010, citing strengthened industrial relationships and global expansion as drivers.
Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Icon reported a dip in operating income in the second quarter but an upturn in new business, and the cash to pursue M&A, make it reasonably positive about the future.
The medical unit of Becton Dickinson (BD) reported a slight increase in revenues in the third quarter driven by solid sales of diabetes products.
Marina Biotech has acquired the intellectual property for the Smarticles liposomal-based delivery system from Novosom AG.
Consolidated sales at Hovione increased by 15 per cent to $144m (€110m) in fiscal 2009.
|
|
Globalisation
More news |
|
|
Patient safety
More news |
|
|
Consolidation
More news |
|
|
Clinical evolution
More news |
